Study #2024-1967
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells with TGF-beta receptor 2 (TGFBR2) Knock Out in Conjunction with Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Dexamethasone, Cyclophosphamide, Fludarabine, Decitabine, TGFBR2 KO CAR27/IL-15 NK cells
Description
The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Malignancies
Study phase:
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?